Clinical Trial Update: Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML [Phase 3]

View source ↗

Summary

Phase 3 study comparing ASTX727 (cedazuridine/decitabine) versus intravenous decitabine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Decitabine (intravenous) (Decitabine)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2024-07-01